Business Wire

Elisa and Vecima Supercharge Cable Network with DAA to Deliver Gigabit Access to Subscribers in Finland

10.5.2022 16:15:00 EEST | Business Wire | Press release

Share

Vecima Networks Inc. (TSX: VCM) announced today that leading Finnish telecommunications operator Elisa has deployed Vecima’s EntraTM Remote MACPHY solution to evolve its network with a next-generation Distributed Access Architecture (DAA). The solution enables Elisa to deploy gigabit broadband and new service experiences to residential subscribers – detached homes and multi-dwelling units – and businesses. In addition, moving to DAA delivers sustainability through digitalization, enabling substantial energy savings.

In Finland’s highly competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s Entra DAA solution boasts flexible access node configurations, a cloud-based access controller, multiple video delivery options, and highly scalable capacity. As Elisa looks to maintain its market-leading position, Entra is well matched to forward-looking, strategic architectural plans.

“We are committed to offering our customers the best possible internet experience,” said Antti Salonen, Head of Technology for Fixed Networks at Elisa. “By deploying the Entra solution, we can move our cable access network to the next generation with higher capacity, new service offerings and automated network operations. Vecima’s unique DAA solution provides a flexible and efficient way to leverage our existing IP network to expand to new areas without the increased costs of additional headend equipment.”

To take advantage of untapped, latent capacity in Hybrid Fiber Coax (HFC) networks, the cable access network must be rearchitected and simplified to eliminate analog/RF transmission, replace, or digitize legacy video, and optimize operational costs. Once deployed, a Distribution Access Architecture increases network capacity and performance, lowers total cost of ownership, and reduces power consumption.

The Vecima SC-1D Entra Access Node offers a Remote MACPHY Device in a compact, European form factor. Elisa will deploy the SC-1D managed by the Vecima Entra Access Controller (EAC), which provides centralized control and leverages software-defined networking principles to pave the way for a platform capable of delivering faster connections to end users.

‟As cable operators contend with changes in the competitive landscape, and ever-growing demands for greater capacity and performance, we see growing momentum in the move to DAA,” said Ryan Nicometo, Senior Vice President and General Manager of Vecima’s Video & Broadband Solutions business. “Elisa is building one of the most innovative DAA deployments in the world, and we’re proud to help enable their strategic vision.”

Further information about Vecima’s Entra solution is available at vecima.com/solutions/distributed-access.

About Elisa

Elisa’s mission is a sustainable future through digitalisation. We are a pioneer in telecommunications and digital services, and in 5G. We provide sustainable solutions for over 2.8 million consumer, corporate and public administration customers in our core markets of Finland and Estonia, as well as in over 100 countries internationally. In Finland, Elisa is a market leader in telecommunications, and our international cooperation partners include Vodafone and Tele2. Elisa is listed on the Nasdaq Helsinki. In 2021, our revenue was EUR 2 billion and we employed 5,300 people in more than 20 countries. Elisa is a carbon-neutral company. Learn more at elisa.com

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.

Learn more at vecima.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations
250-881-1982
invest@vecima.com

Media Relations
bernadette.dunn@vecima.com
david.slovensky@vecima.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye